124 related articles for article (PubMed ID: 37890478)
1. Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer.
Li J; Zheng C; Mai Q; Huang X; Pan W; Lu J; Chen Z; Zhang S; Zhang C; Huang H; Chen Y; Guo H; Wu Z; Deng C; Jiang Y; Li B; Liu J; Yao S; Pan C
Cell Metab; 2023 Nov; 35(11):2044-2059.e8. PubMed ID: 37890478
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
3. miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer.
Wang T; Hao D; Yang S; Ma J; Yang W; Zhu Y; Weng M; An X; Wang X; Li Y; Wu D; Tang J; Yang C; He Y; Zhang L; Jin X; Wang G; Li Z; Zheng T; Meng H; Feng Y; Li X
Cell Death Dis; 2019 Jun; 10(7):495. PubMed ID: 31235732
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.
Guan L; Li Z; Xie F; Pang Y; Zhang C; Tang H; Zhang H; Chen C; Zhan Y; Zhao T; Jiang H; Jia X; Wang Y; Lu Y
J Exp Clin Cancer Res; 2020 Mar; 39(1):53. PubMed ID: 32293499
[TBL] [Abstract][Full Text] [Related]
5. Non-classical estrogen signaling in ovarian cancer improves chemo-sensitivity and patients outcome.
Hao D; Li J; Wang J; Meng Y; Zhao Z; Zhang C; Miao K; Deng C; Tsang BK; Wang L; Di LJ
Theranostics; 2019; 9(13):3952-3965. PubMed ID: 31281524
[TBL] [Abstract][Full Text] [Related]
6. ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models.
Li J; Lu J; Xu M; Yang S; Yu T; Zheng C; Huang X; Pan Y; Chen Y; Long J; Zhang C; Huang H; Dai Q; Li B; Wang W; Yao S; Pan C
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36378528
[TBL] [Abstract][Full Text] [Related]
7. The downregulation of miR-509-3p expression by collagen type XI alpha 1-regulated hypermethylation facilitates cancer progression and chemoresistance via the DNA methyltransferase 1/Small ubiquitin-like modifier-3 axis in ovarian cancer cells.
Wu YH; Huang YF; Wu PY; Chang TH; Huang SC; Chou CY
J Ovarian Res; 2023 Jun; 16(1):124. PubMed ID: 37386587
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicles carrying miR-6836 derived from resistant tumor cells transfer cisplatin resistance of epithelial ovarian cancer via DLG2-YAP1 signaling pathway.
Zou Y; Zhao Z; Wang J; Ma L; Liu Y; Sun L; Song Y
Int J Biol Sci; 2023; 19(10):3099-3114. PubMed ID: 37416779
[No Abstract] [Full Text] [Related]
9. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
10. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
11. Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.
Niimi K; Murakumo Y; Watanabe N; Kato T; Mii S; Enomoto A; Asai M; Asai N; Yamamoto E; Kajiyama H; Shibata K; Kikkawa F; Takahashi M
Cancer Sci; 2014 May; 105(5):545-52. PubMed ID: 24597627
[TBL] [Abstract][Full Text] [Related]
12. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
Han GH; Yun H; Chung JY; Kim JH; Cho H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure and mechanism of a carbon-carbon bond hydrolase.
Timm DE; Mueller HA; Bhanumoorthy P; Harp JM; Bunick GJ
Structure; 1999 Sep; 7(9):1023-33. PubMed ID: 10508789
[TBL] [Abstract][Full Text] [Related]
14. LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model.
Mehdi S; Macdonald E; Galpin K; Landry DA; Rodriguez G; Vanderhyden B; Bachvarov D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679765
[TBL] [Abstract][Full Text] [Related]
15. High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer.
Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
Microrna; 2021; 10(1):51-57. PubMed ID: 33845755
[TBL] [Abstract][Full Text] [Related]
16. Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein-Protein Interaction.
Sail V; Rizzo AA; Chatterjee N; Dash RC; Ozen Z; Walker GC; Korzhnev DM; Hadden MK
ACS Chem Biol; 2017 Jul; 12(7):1903-1912. PubMed ID: 28541665
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
18. Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway.
Endo F; Kubo S; Awata H; Kiwaki K; Katoh H; Kanegae Y; Saito I; Miyazaki J; Yamamoto T; Jakobs C; Hattori S; Matsuda I
J Biol Chem; 1997 Sep; 272(39):24426-32. PubMed ID: 9305902
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update.
Revaux A; Carbonnel M; Kanso F; Naoura I; Asmar J; Kadhel P; Ayoubi JM
Horm Mol Biol Clin Investig; 2020 Feb; 41(3):. PubMed ID: 32083444
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells.
Momeny M; Eyvani H; Barghi F; Ghaffari SH; Javadikooshesh S; Hassanvand Jamadi R; Esmaeili F; Alishahi Z; Zaghal A; Bashash D; Samani FS; Ghaffari P; Dehpour AR; Tavangar SM; Alimoghaddam K; Ghavamzadeh A
Anticancer Drugs; 2018 Nov; 29(10):1011-1020. PubMed ID: 30096128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
